EMSOS studies planned/ ongoing
Minimal Dataset and Data Dictionary for global sarcoma registries
We are happy to present the attached minimal dataset and data dictionary, containing explanations of all data elements. Please incorporate these into your practice and begin collecting data on your patients.
If you would like to receive an example REDCap collection instrument and/or Excel version of the dataset, please contact our research coordinator Abby Grothe (abigail-grothe@uiowa.edu), who will gladly provide these and serve as contact for all questions related to this effort.
Corresponding address
The International Registry Work Group
Ben Miller, Adam Levin, Andreas Leithner, Joanna Szkandera, Marcos Galli, Ricardo Becker, Luke Johnson, Ashish Gulia, Eric Staals, Masood Umer, and Abby Grothe
Contact
Abby Grothe
abigail.grothe@uiowa.edu
Use of 3D printed PSI +/- CAS for bone tumor resection AND for allograft shaping in children and adults – an EMSOS study
We are pleased to invite you to participate in the multicenter study evaluating the use of 3D printed patient specific instruments (PSI) and/or computer assisted surgery (CAS) for both bone tumor resection AND for allograft shaping, in children and adults.
First, planning strategies are evaluated for intercalary and hemicortical resections, including choices on form, shape and size of the osteotomies, pearls and pitfalls of saw guide design, dealing with soft tissues, use of FVFG and type of fixation.
Second, procedural outcome measurements are made and compared on preoperative and postoperative imaging. Gap sizes and procedural accuracy for both host bone and allograft are measured and time to union calculated.
Third, clinical outcomes will be evaluated including time to union, time to full weight bearing and complications related to the techniques used.
Corresponding address
Jasper Gerbers / Michiel van de Sande
Leiden University Medical Center, Leiden, the Netherlands
j.g.gerbers@lumc.nl / majvandesande@lumc.nl
Lizz van der Heijden / Michiel van de Sande
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
l.vanderheijden-9@prinsesmaximacentrum.nl / m.a.j.vandesande-2@prinsesmaximacentrum.nl
Reconstructive options after bone sarcoma resection in children younger than 10 years old – an EMSOS study
We all face dilemmas concerning bone tumor resection and subsequent reconstructive options especially in the smallest children. Therefore, we feel that there is room for an EMSOS study platform on small children and we are pleased to invite you to participate in this multicenter study.
First, different reconstructive options will be evaluated for different localizations and different age ranges, including their oncological and functional outcomes. In addition, limb length discrepancies and growth disorders during further length growth and scheduled secondary surgeries to solve this are also evaluated.
Second, we will send out a survey among orthopedic oncologist including various pediatric cases to see what choices are made, in which patients, whether shared decision making is used, what techniques are preferred (biological, prosthetics, temporary spacer, rotationplasty or amputation etc), when radiotherapy is considered (or not), and how life plans considering length growth and corrections until skeletal maturity are made.
Corresponding address
Lizz van der Heijden / Michiel van de Sande
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
l.vanderheijden-9@prinsesmaximacentrum.nl / m.a.j.vandesande-2@prinsesmaximacentrum.nl
Association between IDH1 R132 Mutations and Prognosis in Chondrosarcoma
We are pleased to invite you to participate in the multicentric retrospective study “Association between IDH1 R132 Mutations and Prognosis in Chondrosarcoma”.
Corresponding address
Giulia Trovarelli
Department of Orthopaedics and Orthopaedic Oncology
Padova, Italy
E-Mail: Giulia.trovarelli@aopd.veneto.it
Study Protocol Proximal Tibia Reconstruction
We herein invite You to participate in the following retrospective multicentre study. Given the fact that the proximal tibia is one of the most frequently affected locations for primary bone tumours, sufficient reconstruction of the adjacent knee joint is of importance. The aim of this multicentre study is to analyse clinical outcomes of patients treated for soft tissue and bone neoplasms (benign, locally aggressive; malignant) of the proximal tibia. As the current literature provides few information on reconstruction-technique-dependent outcomes following surgery for bone and soft tissue neoplasms involving the proximal tibia, the current multicentre retrospective study may allow to draw further conclusions on how to best approach tumours at this specific anatomical location.
Corresponding address
Santiago A. Lozano-Calderon
Paul Jutte
Oncology, Infection, Reconstruction, University Medical Center Groningen
Hanzeplein 1, 9700 RB Groningen, The Netherlands
p.c.jutte@umcg.nl
Ewing-like sarcomas of bone and soft tissues: entities, strategies and outcomes.
Dear Colleagues,
hereby we invite you to participate in the multicentric retrospective study “Ewing-like sarcomas of bone and soft tissues: entities, strategies and outcomes”. The primary aim is to assess mid- to long-term survival of Ewing-like sarcoma patients (both soft tissues and bones). Further endpoints include outcome stratification according to parameters as tumour site and tumour stage at diagnosis, as well as the identification of risk factors independently associated with worse survival.
Corresponding address
Michele Fiore
Department of Orthopedics and Traumatology
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
michelefiore.md@gmail.com
Primary leiomyosarcoma of bone (LMSoB)
Primary leiomyosarcoma of bone (LMSoB) is a rare subtype of bone sarcomas, accounting for less than 0.7% of all malignant bone tumours. The aim of this study is to extend existing data on patients with LMSoB with further cases one to increase the dataset to a sufficient number of patients, eventually allowing to draw conclusions on behavior and treatment response of this extremely rare tumor entity.
Corresponding adress
Dr. Maya Niethard
Clinic for Tumor Orthopedics, Helios Clinic Berlin-Buch
Schwanebecker Chaussee 50
13125 Berlin
Germany
maya.niethard@helios-gesundheit.de
+49 (0)30-9401-55800
A retrospective study of local relapse after high grade osteosarcoma
Aim of this study is to analyse the modalities of diagnosis of LR in high-grade osteosarcoma, pattern of recurrence, treatment of LR and factors influencing post-LR survival (PLRS) focusing on the role of second line chemotherapy, margins and type of surgery
Contact
Emanuela Palmerini, Bologna
Email: emanuela.palmerini@ior.it
EMSOS Study "Angiosarcoma"
Angiosarcoma is the malignant end of the spectrum of vascular tumors, spanning diagnosis including hemangiomas, hemangioendothelioma, well-differentiated and poorly-differentiated angiosarcoma.
Angiosarcoma of bone is rare, accounting for <1% of all primary bone sarcomas and it is associated with a poor prognosis. Although any age can be affected, the incidence is highest between 50 and 70 years of age.
Angiosarcoma of bone may present as unifocal or multifocal disease. The most common locations of unifocal tumor are the long and short tubular bones, followed by the pelvis, and trunk.
Histologically, angiosarcomas of bone are composed of anastomosing vascular channels lined by atypical endothelial cells with enlarged nuclei, prominent nucleoli, and increased mitoses. Inflammatory cells, mostly eosinophils, may be present.
Given the rarity of angiosarcoma of bone, the literature is limited regarding treatment and outcome of patients with this tumor.
The role of chemotherapy and prognostic factors for these patients remain unclear.
Under the auspices of the EMSOS, a retrospective study has been launched with the aim of improving our knowledge on the natural history of the tumor and on prognostic and predictive factors of survival.
Contact
Stefano Ferrari MD
SSD Chemioterapia dei Tumori Muscoloscheletrici
Istituto Ortopedico Rizzoli – WWW.ior.it
Via Pupilli 1, 40136 Bologna. Italy
Stefano.ferrari@ior.it
